HKSE:06955 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:06955 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shandong Boan Biotechnology Co's Enterprise Value is HK$5,251.7 Mil. Shandong Boan Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-477.8 Mil. Therefore, Shandong Boan Biotechnology Co's EV-to-FCF for today is -10.99.
The historical rank and industry rank for Shandong Boan Biotechnology Co's EV-to-FCF or its related term are showing as below:
During the past 4 years, the highest EV-to-FCF of Shandong Boan Biotechnology Co was -10.99. The lowest was -23.14. And the median was -16.37.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-03-03), Shandong Boan Biotechnology Co's stock price is HK$8.89. Shandong Boan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.129. Therefore, Shandong Boan Biotechnology Co's PE Ratio (TTM) for today is 68.91.
The historical data trend for Shandong Boan Biotechnology Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EV-to-FCF | - | - | -22.29 | -23.68 |
Shandong Boan Biotechnology Co Semi-Annual Data | ||||||||
Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | |
EV-to-FCF | Get a 7-Day Free Trial | - | -22.29 | - | -23.68 | - |
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's EV-to-FCF falls into.
Shandong Boan Biotechnology Co's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 5251.685 | / | -477.758 | |
= | -10.99 |
Shandong Boan Biotechnology Co's current Enterprise Value is HK$5,251.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shandong Boan Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-477.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co (HKSE:06955) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Boan Biotechnology Co's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 8.89 | / | 0.129 | |
= | 68.91 |
Shandong Boan Biotechnology Co's share price for today is HK$8.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shandong Boan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.129.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Central Huijin Investment Ltd. | 2201 Interest of corporation controlled by you | |
China Cinda Asset Management Co., Ltd. | 2201 Interest of corporation controlled by you | |
Li Li | 2201 Interest of corporation controlled by you | |
Asiapharm Investments Ltd. | ||
Ginkgo (ptc) Limited | ||
Liu Dianbo | ||
Luye Life Sciences Group Ltd | ||
Luye Pharma Holdings Ltd. | ||
Luye Pharma Hong Kong Limited | ||
Luye Pharmaceutical International Co., Ltd. | ||
Luye Pharmaceutical Investment Co., Ltd. | ||
Nelumbo Investments Limited | ||
Shorea Lbg | ||
Luye Pharma Group Ltd. | ||
Shan Dong Lv Ye Zhi Yao You Xian Gong Si |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.